Adlyxin and Soliqua Join a Crowded Market of Injectable Diabetes Meds

January 2017

Adlyxin (ad-LIKS-in) and Soliqua (soh-LEE-kwa) will be two new once-daily injectable meds for type 2 diabetes...and more are coming.

Adlyxin (lixisenatide) is the sixth GLP-1 agonist for diabetes. Think of it as similar to Byetta...but it's once-daily instead of BID.

Soliqua is the first insulin/GLP-1 agonist combo to hit the market. It contains Lantus (insulin glargine U-100) plus Adlyxin.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Cardiology Limit Dose and Duration of NSAIDs in High-CV-Risk Patients
End-of-Life Care Fine-Tune Medications to Minimize Symptoms at the End of Life
Opioids Consider Treating Your Opioid-Dependent Patients With Buprenorphine/Naloxone
Calcium Help Patients Use Calcium Supplements Safely
Diabetes Adlyxin and Soliqua Join a Crowded Market of Injectable Diabetes Meds
Vaccines Give Pregnant Women the Tdap Vaccine With Every Pregnancy
Acne Know When to Recommend New OTC Differin 0.1% Gel for Acne
Inhalers Prevent Common Inhaler Errors
Pediatrics Use Systemic Quinolones as a Last Resort in Kids...But Not Due to Joint Concerns
Dehydration Consider Diluted Apple Juice an Option for Mild Dehydration in Kids
Obesity & Weight Loss See How Lomaira and Belviq XR Stack Up Against Other Weight Loss Meds
Practice Jardiance (empagliflozin) improving CV outcomes